What's Going On At Gilead

The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and consumer goods editor/analyst Austin Smith discuss topics across the investing world.

In this edition, David and Austin take a closer look at the recent events surrounding Gilead. They go over recent hepatitis C data that caused shares to plunge 15%. Was it a market overreaction, or a real concern for investors? They also discuss Gilead's attempt at expanding Truvada's indications. After the recent drop, is Gilead a stock investors should be snapping up?

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

At the time this article was published Austin Smith has no positions in the stocks mentioned above. David Williamson owns shares of Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson.Motley Fool newsletter services recommendGilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story